Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Gynecologic Oncology

Understanding Your Diagnosis: Squamous Cell Carcinoma of the Cervix

At a Glance

Most cervical squamous cell carcinoma develops after a high-risk HPV infection persists in the cervix’s transformation zone. An HPV-related diagnosis does not reveal when infection occurred or assign blame, while rare HPV-independent tumors may require expert pathology review.

A diagnosis of squamous cell carcinoma (SCC) of the cervix means that cancer has developed in the thin, flat cells—called squamous cells—that line the outer part of your cervix [1]. This is the most common type of cervical cancer, accounting for about 70% of cases worldwide [1][2].

Understanding how this cancer begins can help you make sense of your diagnosis. For the vast majority of women, this journey starts with a common virus and a specific, vulnerable area of the cervix.

The Transformation Zone: Where it Begins

Your cervix is made of two different types of cells. The inner part (the canal leading to the uterus) is lined with gland cells, while the outer part (facing the vagina) is lined with squamous cells. The place where these two cell types meet is called the transformation zone or the squamocolumnar junction [3].

This zone is naturally active, with cells constantly changing and renewing themselves. Because these cells are frequently dividing, they are particularly vulnerable to infection by the human papillomavirus (HPV) [3][4]. Most cervical squamous cell carcinomas begin in this specific area [3].

How HPV Drives Cancer

HPV is an incredibly common virus—so common that most people will have it at some point in their lives [5]. In most cases, your immune system clears the virus on its own within one to two years without you ever knowing it was there [5][6].

Cancer only becomes a risk when a “high-risk” type of HPV (such as HPV16 or HPV18) becomes persistent, meaning your body does not clear it [5][2]. However, it is important to know that most persistent infections do not progress to cancer; only a subset does. When the virus stays in the cells of the transformation zone for a long period, it can begin to rewrite the cells’ instructions using two specific proteins:

  • E6: This viral protein disables a “braking system” in your cells called p53, which normally stops damaged cells from growing [7].
  • E7: This protein interferes with another safeguard called the RB pathway, which controls when cells are allowed to divide [7].

When these two safeguards are down, cells can grow uncontrollably, eventually turning from a precancerous lesion into invasive cancer [8][9].

Understanding the HPV Connection and Stigma

Finding out that your cancer is linked to an HPV infection can bring up a range of emotions, including shock, guilt, or shame. It is important to know that an HPV-related diagnosis is not a reflection of your lifestyle or choices, and it is not a moral judgment [P-091].

  • HPV is quiet: The virus can be detected long after initial exposure, and the timing of when you were infected is usually unknowable [5][10]. A positive test today may represent a newly detected infection, or the reactivation of an old one.
  • It is not about blame: While a higher number of lifetime sexual partners increases the statistical chance of exposure, this is not a measure of character. Research shows that the specific type of HPV you have and its persistence are the main drivers of risk [11].
  • It is a medical reality: Almost every sexually active person will encounter HPV [5]. For reasons we are still studying—which may include genetics, smoking, or immune health—the virus simply doesn’t leave the body in some people [12][13].

Your medical team is focused on treating the cancer, not judging how it began. You deserve the same compassion and high-quality care as anyone facing a medical challenge [14]. (Note: While the HPV vaccine prevents new infections, it does not treat an existing cancer; you can discuss with your clinician if vaccination is right for you moving forward.)

Rare HPV-Independent Subtypes

While roughly 95% of cervical squamous cell carcinomas are caused by HPV, doctors now recognize a very small group of “HPV-independent” cancers [15][16]. True HPV-independent cervical SCC is exceptionally uncommon and diagnostically challenging. These are rare variants that develop through different genetic mutations (often involving the TP53 gene) and are not caused by a viral infection [17][18].

These cases are often found in older women and may be harder to detect through standard HPV-based screening [19][20]. If your pathology report mentions that your tumor is “HPV-negative,” this could sometimes just mean the testing reached its limit or the sample was small. Your doctor will use specialized tests—like looking for a surrogate protein called p16 or checking p53 patterns—and may recommend an expert pathology review to confirm this rare subtype and plan your care accordingly [16][21].

What the Research Tells Us

Scientists and doctors agree on several key facts about this diagnosis:

  • HPV is the primary driver: High-risk HPV is responsible for the vast majority of these cancers [2].
  • Persistence is key: A one-time positive HPV test is common, but a virus that persists can lead to cellular changes [5].
  • Early detection works: Because this cancer usually develops slowly over many years, many cases are highly treatable when caught early [22][23].

There are still things we are learning, such as why some people’s immune systems clear the virus while others do not, and how the vaginal microbiome (the healthy bacteria in the vagina) might play a role in helping or hindering the virus [13].

Your care team will use this biological understanding to tailor your treatment. Whether your cancer is HPV-associated or independent, the goal remains the same: treating the cells and supporting your health [24].

Common questions in this guide

What is squamous cell carcinoma of the cervix?
Squamous cell carcinoma of the cervix is the most common type of cervical cancer. It begins in the thin, flat cells lining the outer cervix, often in the transformation zone where the inner and outer cell types meet.
How can HPV lead to cervical squamous cell carcinoma?
Most cervical squamous cell carcinomas are linked to a high-risk HPV infection that remains in cervical cells instead of clearing. Over time, viral proteins can disable cell safeguards and allow abnormal cells to grow; most HPV infections, including most persistent infections, do not become cancer.
Does an HPV-positive result show when I became infected?
An HPV-positive result does not usually show when the infection began. HPV can be detected long after exposure, and a positive result may reflect a newly detected infection or reactivation of an older one.
Does an HPV-related cervical cancer diagnosis mean I did something wrong?
No. HPV is extremely common, and the timing of infection is usually unknowable. An HPV-related diagnosis is a medical condition, not a measure of your choices, character, or moral worth.
What is the transformation zone of the cervix?
The transformation zone is the area where gland cells lining the inner cervical canal meet squamous cells lining the outer cervix. These cells are actively changing and dividing, which helps explain why many cervical squamous cell carcinomas begin there.
What does it mean if my cervical tumor is HPV-negative?
An HPV-negative result can sometimes reflect a testing limitation or a small sample rather than a truly HPV-independent tumor. Because true HPV-independent cervical squamous cell carcinoma is rare, your doctor may use p16 and p53 patterns and request expert pathology review.
Can the HPV vaccine treat cervical squamous cell carcinoma?
No. The HPV vaccine helps prevent new HPV infections, but it does not treat an existing cervical cancer. Ask your clinician whether vaccination is appropriate for you moving forward.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my tumor been confirmed as HPV-associated or HPV-independent by an expert pathologist?
  2. 2.Was my diagnosis based on a specific HPV genotype, such as HPV16 or HPV18?
  3. 3.Does my pathology report show a 'block' pattern for p16, and what does that mean for my diagnosis?
  4. 4.Was my cancer found in the 'transformation zone' of my cervix?
  5. 5.Are there lifestyle factors, like smoking cessation, that I should address to support my body during treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.

    Arbyn M, Weiderpass E, Bruni L, et al.

    The Lancet. Global health 2020; (8(2)):e191-e203 doi:10.1016/S2214-109X(19)30482-6.

    PMID: 31812369
  2. 2

    Carcinogenic human papillomavirus infection.

    Schiffman M, Doorbar J, Wentzensen N, et al.

    Nature reviews. Disease primers 2016; (2()):16086 doi:10.1038/nrdp.2016.86.

    PMID: 27905473
  3. 3

    Oxidative Stress, Inflammation, and Antioxidant Strategies in Cervical Cancer-A Narrative Review.

    Tomaziu-Todosia Anton E, Anton GI, Scripcariu IS, et al.

    International journal of molecular sciences 2025; (26(10)) doi:10.3390/ijms26104961.

    PMID: 40430101
  4. 4

    The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review.

    Graham SV

    Clinical science (London, England : 1979) 2017; (131(17)):2201-2221 doi:10.1042/CS20160786.

    PMID: 28798073
  5. 5

    The natural history of human papillomavirus infection.

    de Sanjosé S, Brotons M, Pavón MA

    Best practice & research. Clinical obstetrics & gynaecology 2018; (47()):2-13 doi:10.1016/j.bpobgyn.2017.08.015.

    PMID: 28964706
  6. 6

    Subversion of Host Innate Immunity by Human Papillomavirus Oncoproteins.

    Lo Cigno I, Calati F, Albertini S, Gariglio M

    Pathogens (Basel, Switzerland) 2020; (9(4)) doi:10.3390/pathogens9040292.

    PMID: 32316236
  7. 7

    The TP53 "rs 1042522″ Polymorphism and its association with precancerous cervical lesions progression among Tunisian women.

    Ben Jemia Z, Fehri E, Ardhaoui M, et al.

    Diagnostic microbiology and infectious disease 2025; (113(3)):116981 doi:10.1016/j.diagmicrobio.2025.116981.

    PMID: 40609119
  8. 8

    High-Risk Alphapapillomavirus Oncogenes Impair the Homologous Recombination Pathway.

    Wallace NA, Khanal S, Robinson KL, et al.

    Journal of virology 2017; (91(20)) doi:10.1128/JVI.01084-17.

    PMID: 28768872
  9. 9

    5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression.

    Morel A, Baguet A, Perrard J, et al.

    Oncotarget 2017; (8(28)):46163-46176 doi:10.18632/oncotarget.17575.

    PMID: 28521287
  10. 10

    The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications.

    Hu Z, Ma D

    Cancer medicine 2018; (7(10)):5217-5236 doi:10.1002/cam4.1501.

    PMID: 30589505
  11. 11

    Risk factors for HPV infection and high-grade cervical disease in sexually active Japanese women.

    Yamaguchi M, Sekine M, Hanley SJB, et al.

    Scientific reports 2021; (11(1)):2898 doi:10.1038/s41598-021-82354-6.

    PMID: 33536516
  12. 12

    HPV-Driven Cervical Carcinogenesis: Genetic and Epigenetic Mechanisms and Diagnostic Approaches.

    Legaki E, Lappa T, Prasoula KL, et al.

    International journal of molecular sciences 2026; (27(2)) doi:10.3390/ijms27020803.

    PMID: 41596450
  13. 13

    The interplay between HPV, vaginal microbiota and host immunity in cervical carcinogenesis.

    Moghaddam NA, Mohabbat A, Jigheh MP, et al.

    Discover oncology 2026; (17(1)).

    PMID: 42223784
  14. 14

    Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.

    Ye J, Zheng L, He Y, Qi X

    MedComm 2023; (4(5)):e368 doi:10.1002/mco2.368.

    PMID: 37719443
  15. 15

    Invasive Squamous Cell Carcinoma of the Cervix: A Review of Morphological Appearances Encountered in Human Papillomavirus-associated and Papillomavirus-independent Tumors and Precursor Lesions.

    Stolnicu S, Allison D, Patrichi A, et al.

    Advances in anatomic pathology 2024; (31(1)):1-14 doi:10.1097/PAP.0000000000000411.

    PMID: 37638549
  16. 16

    Diagnostic value of cytology in detecting human papillomavirus-independent cervical malignancies: a nation-wide study in Korea.

    Jung HR, Shin J, Yoo CW, et al.

    Journal of pathology and translational medicine 2025; (59(6)):444-452 doi:10.4132/jptm.2025.10.21.

    PMID: 41266097
  17. 17

    The Histologic and Molecular Spectrum of Highly Differentiated HPV-independent Cervical Intraepithelial Neoplasia.

    Regauer S, Reich O

    The American journal of surgical pathology 2023; (47(8)):942-949 doi:10.1097/PAS.0000000000002067.

    PMID: 37283469
  18. 18

    HPV-negative Squamous Cell Carcinomas of the Cervix With Special Focus on Intraepithelial Precursor Lesions.

    Regauer S, Reich O, Kashofer K

    The American journal of surgical pathology 2022; (46(2)):147-158 doi:10.1097/PAS.0000000000001778.

    PMID: 34387215
  19. 19

    Cervical Human Papillomavirus-Independent Squamous Cell Carcinoma: A Clinicopathological Review and Outcomes Analysis Compared With Human Papillomavirus-Associated Squamous Cell Carcinoma.

    Stolnicu S, Rakislova N, Morató A, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2025; (38(6)):100742 doi:10.1016/j.modpat.2025.100742.

    PMID: 40010435
  20. 20

    HPV-independent squamous sell carcinoma of cervix: a clinicopathological, immunohistochemical, and molecular analysis of six cases.

    Kır G, Erbağcı A, Özen F, et al.

    Virchows Archiv : an international journal of pathology 2025; (487(4)):775-786 doi:10.1007/s00428-025-04113-6.

    PMID: 40347270
  21. 21

    Incidence and Clinicopathologic Characteristics of Human Papillomavirus-independent Invasive Squamous Cell Carcinomas of the Cervix: A Morphologic, Immunohistochemical, and Human Papilloma-Virologic Study of 670 Cases.

    Stolnicu S, Allison D, Praiss AM, et al.

    The American journal of surgical pathology 2023; (47(12)):1376-1389 doi:10.1097/PAS.0000000000002122.

    PMID: 37702216
  22. 22

    A Review of Cervical Cancer: Incidence and Disparities.

    Buskwofie A, David-West G, Clare CA

    Journal of the National Medical Association 2020; (112(2)):229-232 doi:10.1016/j.jnma.2020.03.002.

    PMID: 32278478
  23. 23

    Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction.

    Guo F, Cofie LE, Berenson AB

    American journal of preventive medicine 2018; (55(2)):197-204 doi:10.1016/j.amepre.2018.03.013.

    PMID: 29859731
  24. 24

    Role of human papillomavirus status in the classification, diagnosis, and prognosis of malignant cervical epithelial tumors and precursor lesions.

    Stolnicu S

    Pathologie (Heidelberg, Germany) 2025; doi:10.1007/s00292-025-01517-8.

    PMID: 41335338

This page explains how HPV and other factors relate to cervical squamous cell carcinoma for informational purposes only and does not constitute medical advice; your gynecologic oncology and pathology teams should interpret your results and advise you about care.

Get notified when new evidence is published on Squamous cell carcinoma of the cervix uteri.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.